Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

Baker Capital Strategies

Free Registration

Register for access to news, tools, alerts and reports.

THEMA Basic included at launch.

Use at least 8 characters.

Current Report · Items 2.02, 9.01 · 8-K

Stereotaxis, Inc.

STXSNYSE_AMERICANEQUITYCurrent

Results of Operations and Financial Condition

Item Results 2.02 of Operations and Financial Condition On May 12, 2026, Stereotaxis, Inc. (the “Company”) issued a press release (the “Earnings Press Release”) setting forth its financial results for the 2026 first quarter. A copy of the Earnings Press Release is being filed as Exhibit 99.1 hereto, and the statements contained therein are incorporated by reference herein.

Filed May 12, 2026Accepted May 12, 2026, 4:10 PM EDTCIK 1289340Accession 0001493152-26-022488
Share

Company context

Current securities

Recent company filings

  1. EFFECT filingAug 13, 2026
  2. EFFECT filingAug 13, 2026
  3. 424B3 filingAug 13, 2026
  4. 424B3 filingAug 13, 2026
  5. 10-Q filingAug 12, 2026

Disclosure sections

Items 2.02, 9.01

Select an item to read the extracted section. The as-filed document remains the primary evidence.

Item 2.02Item 2.02 - Results of Operations
Item Results 2.02 of Operations and Financial Condition On May 12, 2026, Stereotaxis, Inc. (the “Company”) issued a press release (the “Earnings Press Release”) setting forth its financial results for the 2026 first quarter. A copy of the Earnings Press Release is being filed as Exhibit 99.1 hereto, and the statements contained therein are incorporated by reference herein.
Filed exhibits (1)
EX-99.1 (by filename) ex99-1.htm

EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 Stereotaxis Reports 2026 First Quarter Financial Results & Business Updates Proprietary robotically-navigated MAGiC catheter received U.S. FDA approval in January and is now being utilized at multiple sites across the United States as well as Europe Synchrony digital operating room system received U.S. FDA clearance in April and initial orders and shipments are ongoing ──────────────────────────────────────────────────────────────────────────────────────────────────── Definitive agreement to acquire Robocath creates a leading robotic platform, combining complementary technologies to deliver next-generation fully-integrated robotic solutions for the full spectrum of endovascular procedures St. Louis, MO, May 12, 2026 (Globe Newswire) - Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported business updates and financial results for the first quarter ended March 31, 2026. “Stereotaxis is in one of the most exciting periods of its history. We are achieving significant regulatory approvals, executing strategic acquisitions, and witn…

Open exhibit ↗